Cell Therapeutics approves amendment of shareholder rights plan

theflyonthewall.com

Cell Therapeutics announced that its board has approved certain amendments to CTI's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights under the Rights Plan from $14.00 to $8.00 and to extend the "final expiration date" from the close of business on the third anniversary of January 7, to the close of business on December 3, 2015. The Rights were initially distributed as a dividend on each share of CTI's common stock outstanding on the Record Date and currently trade with each outstanding share of CTI's common stock.

View Comments (0)